Piper Jaffray analyst Steven Breazzano said the detailed results from AstraZeneca's (AZN) SOLO-2 maintenance study of Lynparza highlights a PFS benefit and favorable hazard ratio, which he views as confirming that PARP inhibitors are "more similar than different." He believes this data provides a favorable read through to Clovis' (CLVS) Rubraca, which he thinks will "succeed with a similar magnitude of benefit" in the ARIEL3 maintenance study. Breazzano keeps an Overweight rating and $77 price target on Clovis shares, which finished up 10.5% at $66.95 following AstraZeneca's announcement.